Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease and cardiovascular disease. However, whether lowering serum UA can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients, is still a matter of discussion. Evidence from observational studies suggests possible cardiovascular benefits associated with ULT, in particular for the XO-inhibitors, while the evidence from randomized controlled trials is scarce and somewhat conflicting. These discrepancies could be explained by the existence of different phenotypes across hyperuricemic patients with a non-homogeneous distribution of clinical benefits from ULT.

Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark / Desideri G., Borghi C.. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - STAMPA. - 113:(2023), pp. 10-12. [10.1016/j.ejim.2023.04.006]

Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark

Borghi C.
Ultimo
Conceptualization
2023

Abstract

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease and cardiovascular disease. However, whether lowering serum UA can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients, is still a matter of discussion. Evidence from observational studies suggests possible cardiovascular benefits associated with ULT, in particular for the XO-inhibitors, while the evidence from randomized controlled trials is scarce and somewhat conflicting. These discrepancies could be explained by the existence of different phenotypes across hyperuricemic patients with a non-homogeneous distribution of clinical benefits from ULT.
2023
Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark / Desideri G., Borghi C.. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - STAMPA. - 113:(2023), pp. 10-12. [10.1016/j.ejim.2023.04.006]
Desideri G., Borghi C.
File in questo prodotto:
File Dimensione Formato  
Desideri G_Xanthine oxidase inhibition_Eur J Int Med.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.18 MB
Formato Adobe PDF
1.18 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/951039
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 1
social impact